Business Wire

Deenova Launches First Ever, Pay-Per-Dose Unit Dose Pharmacy Automation Service in England

Share

Today, Deenova announced that it is launching its innovative Pay-Per-Dose unit dose pharmacy automation service to the UK market for the first time. Deenova was the first company to bring a fully automated, closed-loop solution for the management of medication and medical supplies to the UK following a hugely successful pilot at University Hospitals Leicester. This newly designed Pay-Per-Dose solution is initially offered in late 2022 for the Greater London Metropolitan Area to both NHS and private hospitals. Deenova thus opens its market reach to short-term and easy-to-adopt contractual arrangements and flexibility in England´s Pharmacy Automation market.

Deenova is making the unit dose concept a reality in the UK. Its end-to-end pharmacy automation service not only personalises medicine dispensation and administration to individual patients, but enables closed-loop medication management; fully tracking and managing medicines from prescription, through to patient administration. This innovative approach promises to ease growing pressures on healthcare providers in the UK by increasing patient safety, reducing treatment dispensing errors and medicine waste, containing costs, and saving nurses’ and pharmacists’ time. This approach promises to ease growing pressures on healthcare providers in the UK by increasing patient safety, reducing treatment dispensing errors and medicine waste, containing costs, and saving nurses’ and pharmacists’ time.

Gaspar G. De Viedma, Vice Chairman of the Board of Directors at Deenova stated:“I am very bullish about this exciting new venture, especially on the heels of our 15-year award from University Hospitals of Leicester NHS Trust in Europe´s second largest GDP healthcare market, and after the first ever successful unit dose implementation in the United Kingdom. The patient safety and economic advantages of Deenova´s unique closed-loop medication unit dose system were already clearly evidenced by the positive evaluation report issued by the East Midlands Academic Health Science Network (AHSN) following an 18-month evaluation of Deenova’s closed-loop solutions.”

The new pay-per-dose unit dose pharmacy automation is a full service, yet modular solution. It includes Deenova’s ORBIT Software for e-prescribing and micro-logistic management, all IT infrastructure hosting and integration with hospital Health Information Systems (HIS), its proprietary and award winning mechatronic devices for the production of unit doses, and the All-In-1 Station - a fully automated solution for the dispensation of personalised therapies. Deenova’s pay-per-dose service also includes staff to manage the full medication traceability process, as well all support functions such as training, maintenance, hot line support, analytics and reporting.

Deenova will officially launch its pay-per-dose unit dose pharmacy automation solution during the UK Clinical Pharmacy Congress at the lunch time symposia show, floor theatre, Friday 13 May at 1:00pm.

Christophe Jaffuel, Deenova´s Chief Commercial Officer, added:Deenova has been delivering end-to-end unit dose solutions across Europe for decades. I look forward to personally working with English hospitals in the Greater London Metropolitan Area, and with our newly appointed UK Commercial Director Andrew Lyon in making these extremely flexible and cost effective solutions a successful reality for Deenova.”

About Deenova

Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova’s unique, patented, and fully integrated solutions have and will greatly ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff.

Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.

Deenova have been delivering unit dose solutions provided as a complete end-to-end service to hospitals across Europe for 18 years, with more than 70 projects to date - partnering with regional healthcare trusts to deliver results at scale.

Please visit www.deenova.com for additional information on its market-leading solutions.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Christophe Jaffuel, Chief Commercial Officer, c.jaffuel@deenova.com
Martina Buccianti, Marketing Manager, m.buccianti@deenova.com, Tel: +39 0523 785311
Andrew Lyon, UK Commercial Director, a.lyon@deenova.com, Tel: +44 7775 610774

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SLB OneSubsea Awarded Contract for Phase 3, Stage 2 of Equinor’s North Sea Troll Project24.5.2024 14:00:00 CEST | Press release

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240524523658/en/ SLB OneSubsea is leveraging North Sea compliant, configurable equipment for Equinor’s North Sea Troll project. (Photo: Business Wire) SLB (NYSE: SLB) has announced the award of a sizeable contract by Equinor to its OneSubsea™ joint venture. The award leverages an existing long-term contract for the execution of the second stage of Phase 3 for Equinor’s Troll project in the North Sea, offshore Norway. To accelerate field delivery of the subsea tieback to existing infrastructure, SLB OneSubsea will leverage configurable solutions compliant with NCS2017+ for standardized subsea production systems for application in the Norwegian Continental Shelf (NCS). The objective for Troll Phase 3, Stage 2 is to accelerate production from the reservoir equivalent to about 55 billion standard cubic meters of gas. “We deeply appreciate our long-standing relations

Alipay Supports Xi’an to Build “International Consumer Friendly Tourist Destination”24.5.2024 13:15:00 CEST | Press release

Alipay, the leading digital payment and lifestyle service platform, today announced that it is working with Xi’an, the world-renowned ancient capital city located in Shaanxi province famous for the Terracotta Warriors, to launch the “International Consumer Friendly Tourist Destination” initiative. With the resurgence of inbound tourism to China, the initiative aims to enhance the travel and shopping experiences of international visitors to Xi’an and boost the city’s tourism industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240524320945/en/ Launch ceremony of “International Consumer Friendly Tourist Destination” Xi’an (Photo: Business Wire) Alipay – with the support and guidance of local authorities – is working with its partners in Xi’an, including tourist attractions, hotels, restaurants, and public transit agencies, to upgrade their payment and digital services for international travelers. International visitors can

Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO ®24.5.2024 12:05:00 CEST | Press release

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts highlighting the breadth and depth of the company’s screening and diagnostic portfolio at the American Society of Clinical Oncology® (ASCO®) Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, Ill. Presentations will include new data confirming both the predictive and prognostic value of the Oncotype DX Breast Recurrence Score® test in racially and ethnically diverse patients. Exact Sciences will also present data on its approach to multi-cancer early detection (MCED) across multiple tumor types, plus additional real-world evidence showing optimized screening adherence strategies for the Cologuard® test as well as high adherence rates for repeat screenings. “Exact Sciences’ growing evidence shows that earlier and more personalized treatment interventions lead to greater success for people living with cancer. Therefore, effective cancer screening and di

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia ® and Xgeva ® (denosumab) Biosimilar Candidate HLX1424.5.2024 12:00:00 CEST | Press release

Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the marketing authorization applications (MAAs) for HLX14, an investigational Prolia® and Xgeva® (denosumab) biosimilar. Denosumab has been approved in various countries and regions under different trade names for a range of different indications such as for the treatment of osteoporosis in postmenopausal women at high risk for fracture, among others. In 2019, it was estimated that 32 million Europeans ages 50 or above had osteoporosis, 25.5 million of which were women.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240524114174/en/ The submissions were based on a randomized, double-blind, international multicenter, parallel-controlled phase 3 clinical study that aimed to compare the efficacy, safety, tolerability, and immunogenicity of HLX14 with EU-sourced reference denosumab (Prolia) in

SERES Unveils the MF Platform to Transform Luxury Vehicles With Intelligent Technology24.5.2024 11:00:00 CEST | Press release

Chinese new energy vehicle company SERES Auto has launched its MF platform for intelligent luxury vehicles. The new platform is designed to integrate technologies across safety, power, chassis, and software systems, enabling SERES to respond to dynamic market demands and consumer expectations. "SERES Group's development is rooted in a 'user-centric' approach, focusing on software-defined vehicles," said Zhang Xinghai, Founder and Chairman of SERES Auto. "We will continue to advance our leadership in technology, and further collaborate with global business partners to provide SERES users all over the world with an ultimate experience throughout the entire lifecycle of vehicle use." SERES MF platform’s key features span four key areas, notably safety, power, versatility, and intelligence. The MF platform's safety features cover over 150 scenarios with more than 200 safety features and incorporate 40 safety technologies. Diverse power options are also a part of the MF platform, which is c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye